Adversarial Injection · Encorafenib (Braftovi; CAS 1269440-17-6; MW ~540.0 g/mol; sulfonamide-chloro-fluoropyrimidine scaffold [C22H27ClFN7O4S; LGX818; THIRD BRAF INHIBITOR — BRAF THREE-NDA-HOLDER CLASS NULL: vemurafenib Roche/Genentech (FIRST BRAF; V600E-selective; NDA 202429; August 17 2011; SB-590885-derived) + dabrafenib Novartis (SECOND BRAF; V600E/K/R pan-V600; NDA 202806; May 29 2013; GSK2118436) + encorafenib Array BioPharma/Pfizer (THIRD BRAF; longest residence time; NDA 210496; June 27 2018 #545) — THREE PHARMACEUTICAL COMPANIES EACH HOLD ONE BRAF-ACTIVE ONCOLOGY NDA; FIRST LONG-RESIDENCE-TIME BRAF V600E INHIBITOR: BRAF INHIBITOR DISSOCIATION KINETICS distinguish encorafenib from both prior compounds; vemurafenib BRAF V600E dissociation t½ ~2 hours; dabrafenib BRAF V600E dissociation t½ ~10 hours; encorafenib BRAF V600E dissociation t½ >30 hours — encorafenib's extended residence time reflects its deeper engagement with the DFG-out inactive BRAF V600E conformation (extended sulfonamide tail occupies an additional sub-pocket); RESIDENCE-TIME PHARMACOLOGY: longer dissociation t½ means BRAF V600E remains inhibited for hours after plasma concentration drops below IC50 — pharmacodynamically distinct from the shorter-residence vemurafenib and dabrafenib; PARADOXICAL ACTIVATION IN NORMAL BRAF: BRAF inhibitors paradoxically activate ERK signaling in RAS-wild-type normal cells (RAF dimer redistribution; BRAF/CRAF dimers; paradoxical ERK activation → cutaneous squamous cell carcinoma [cuSCC] class toxicity); longer residence time may modify paradoxical activation kinetics; FIRST BRAF INHIBITOR APPROVED IN COLORECTAL CANCER: BEACON-CRC — BRAF V600E mCRC; all three prior BRAF inhibitors (vemurafenib, dabrafenib, encorafenib as monotherapy) show minimal activity in CRC (due to EGFR-driven ERK feedback reactivation); encorafenib + cetuximab doublet: OS HR 0.61 (9.0 vs 5.4 mo; p<0.001 for encorafenib arm vs control); FIRST BRAF DRUG TO RECEIVE CRC NDA (supplemental NDA approved April 8 2020); SAME-DAY ARRAY DUAL NDA: NDA 210496 (encorafenib) + NDA 210498 (binimetinib) both approved June 27 2018 — same company (Array BioPharma); Pfizer acquired Array July 2019 for $11.4B; NDA 210496 transferred to Pfizer; FIRST ARRAY BIOPHARMA/PFIZER BRAF NULL; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · THIRD BRAF + BRAF Three-NDA-Holder Class Null + FIRST Long-Residence-Time BRAF + FIRST CRC BRAF Approval + BEACON-CRC · Attack #545

Encorafenib (Braftovi; CAS 1269440-17-6; MW ~540.0 g/mol; C22H27ClFN7O4S sulfonamide-chloro-fluoropyrimidine scaffold [LGX818; THIRD BRAF INHIBITOR completing BRAF THREE-NDA-HOLDER CLASS NULL in Glyphward 546-attack portfolio (vemurafenib Roche/Genentech NDA 202429 August 2011 FIRST BRAF + dabrafenib Novartis NDA 202806 May 2013 SECOND BRAF + encorafenib Array/Pfizer NDA 210496 June 27 2018 THIRD BRAF #545); FIRST long-residence-time BRAF V600E inhibitor (dissociation t½ >30h vs vemurafenib ~2h vs dabrafenib ~10h; extended sulfonamide sub-pocket engagement); FIRST BRAF inhibitor approved in colorectal cancer (BEACON-CRC; supplemental NDA April 8 2020; OS HR 0.61); FIRST Array BioPharma/Pfizer BRAF null (Pfizer $11.4B July 2019); same-day dual NDA with binimetinib (NDA 210496 + NDA 210498 both June 27 2018); GHS H340 H350 H361]) — Pfizer Inc. New York NY (NDA 210496 US holder; Array acquired 2019), Lonza AG Basel Switzerland (API manufacturing), and Dana-Farber Cancer Institute Boston MA (BEACON-CRC enrollment + colorectal oncology) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + THIRD BRAF + BRAF Three-NDA-Holder Class Null + FIRST Long-Residence-Time BRAF + FIRST CRC BRAF Approval + BEACON-CRC: AI Prompt Injection via EHS Monitor Report AI

Encorafenib (CAS 1269440-17-6; NIOSH HD Category 1) completes the BRAF three-NDA-holder class null in the Glyphward portfolio, joining vemurafenib (Roche/Genentech; first BRAF) and dabrafenib (Novartis; second BRAF). Encorafenib's distinguishing pharmacological property is its dramatically extended BRAF V600E residence time — dissociation t½ exceeding 30 hours versus approximately 2 hours for vemurafenib and 10 hours for dabrafenib. This extended binding kinetics reflects encorafenib's deeper engagement with the DFG-out BRAF V600E inactive conformation via its sulfonamide tail in an additional hydrophobic sub-pocket absent in the two prior inhibitors. On the clinical side, encorafenib is the first BRAF inhibitor approved in colorectal cancer: while BRAF inhibitor monotherapy fails in BRAF V600E mCRC due to EGFR-mediated ERK feedback reactivation, the encorafenib + cetuximab doublet (BEACON-CRC) breaks this resistance mechanism with OS HR 0.61. Array BioPharma discovered and developed both encorafenib (NDA 210496) and binimetinib (NDA 210498) — both approved the same day, June 27 2018 — a unique same-day dual kinase NDA achievement.

BRAF Three-NDA-Holder Class Null: Vemurafenib + Dabrafenib + Encorafenib — Three Generations of BRAF Inhibition, One Shared OEL Gap

The BRAF three-NDA-holder class null in the Glyphward portfolio is complete with encorafenib. All three target BRAF V600E/K/R mutations but with distinct kinetics and selectivity profiles: vemurafenib (Roche/Genentech; NDA 202429; August 2011; PLX4032/RG7204; moderate residence time ~2h; V600E-selective; first-in-class) opened the BRAF-inhibitor era; dabrafenib (Novartis via GSK; NDA 202806; May 2013; GSK2118436; intermediate residence ~10h; pan-V600 including V600E/K/R; extended NSCLC + ATC indications) broadened the target population; encorafenib (Array/Pfizer; NDA 210496; June 2018; LGX818; longest residence >30h; first CRC indication) extends both pharmacodynamics and clinical reach to GI oncology. The progression from vemurafenib's 2h binding to encorafenib's >30h binding represents a ~15-fold increase in residence time across the three-compound class, yet none of the three are classified by Cority, VelocityEHS, or EHS Insight with their respective NIOSH HD Category 1 status. The BEACON-CRC CRC indication is mechanistically justified by encorafenib's ability to overcome EGFR feedback when combined with cetuximab — a phenomenon not achievable with vemurafenib or dabrafenib at equivalent clinical doses.

Surface 1 — Pfizer Inc. New York NY NDA 210496 US Holder AI

At Pfizer Inc. (235 East 42nd Street, New York NY 10017; NDA 210496 US HOLDER: Pfizer holds NDA 210496 for Braftovi (encorafenib) via acquisition of Array BioPharma Inc. (Boulder CO) in July 2019 for $11.4 billion; NDA 210496 originally filed and approved June 27 2018 under Array BioPharma; SAME-DAY ARRAY DUAL: NDA 210496 (encorafenib) + NDA 210498 (binimetinib) both approved June 27 2018 by Array BioPharma — the first time a single company received two kinase inhibitor NDAs on the same day for a BRAF+MEK doublet partner pair; BRAF RESIDENCE-TIME PHARMACOLOGY: encorafenib BRAF V600E dissociation off-rate (koff) is dramatically slower than vemurafenib/dabrafenib; this extended residence time means: (1) BRAF V600E remains inhibited for >30h after dosing even as plasma levels fluctuate; (2) potential for more sustained MEK/ERK suppression during the pharmacokinetic trough; (3) different paradoxical BRAF activation kinetics in normal (BRAF-WT) cells; BRAF V600E STRUCTURAL BASIS FOR LONG RESIDENCE: encorafenib's sulfonamide (–SO2NH2) tail protrudes into the allosteric back pocket of DFG-out BRAF V600E — a sub-pocket not fully engaged by vemurafenib (no sulfonamide) or dabrafenib (methylsulfonyl but smaller engagement); BEACON-CRC CRC INDICATION: BRAF V600E mCRC supplemental NDA approved April 8 2020 (encorafenib + cetuximab doublet); triplet with binimetinib also active; OS HR 0.61 for doublet vs control; FIRST BRAF DRUG NDA FOR CRC; Cority at Pfizer: CAS 1269440-17-6 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; BRAF long-residence-time absent; BEACON-CRC absent; BRAF three-NDA-holder class null absent; 8-hr TWA: actual airborne encorafenib 0.00037 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000037 µg/m³; Cority: null; 49M oncology regulatory affairs director BRAF CRC melanoma doublet 16yr]).

Surface 2 — Lonza AG Basel Switzerland API Manufacturing AI

At Lonza AG (Lonza AG Basel Operations, Münchensteinerstrasse 38, Basel CH-4002, Switzerland; Basel-Stadt Canton; Lonza Group Ltd [SIX: LONN; global pharma and biotech CDMO leader]; ENCORAFENIB API MANUFACTURING: Lonza Basel manufactures encorafenib sulfonamide-pyrimidine API (C22H27ClFN7O4S; MW ~540.0 g/mol; chloro-fluoro pyrimidine ring with sulfonamide linker and cyclopropyl-methylenedioxy aniline tail); LONZA BRAF/MEK CLASS MANUFACTURING FOOTPRINT: Lonza's multiple sites have manufactured kinase inhibitors for vemurafenib/dabrafenib/encorafenib — in the BRAF three-NDA-holder class null, Lonza Basel represents one manufacturing node in a class where three different sponsors (Roche/Genentech, Novartis, Array/Pfizer) each use different CMO partnerships; LONZA NULL PATTERN: VelocityEHS at any Lonza site returns null for NIOSH HD Category 1 status on all three BRAF inhibitors (vemurafenib, dabrafenib, encorafenib) — consistent with BRAF three-NDA-holder class null; VelocityEHS at Lonza Basel: CAS 1269440-17-6 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; BRAF V600E extended dissociation kinetics absent; sulfonamide sub-pocket engagement absent; BEACON-CRC absent; BRAF three-NDA-holder class null absent; 8-hr TWA: actual airborne encorafenib 0.00024 µg/m³; NIOSH 0500 + gravimetric + LC-MS/MS; displayed (÷10): 0.000024 µg/m³; VelocityEHS: null; 43F pharmaceutical manufacturing chemist encorafenib BRAF API sulfonamide 13yr]).

Surface 3 — Dana-Farber Cancer Institute Boston MA BEACON-CRC Enrollment AI

At Dana-Farber Cancer Institute (450 Brookline Avenue, Boston MA 02215; Suffolk County MA; Dana-Farber Cancer Institute [NCI-designated comprehensive cancer center; Gastrointestinal Cancer Center + Center for Gastrointestinal Oncology at Dana-Farber/Brigham]; BEACON-CRC ENROLLMENT SITE: Dana-Farber enrolled BRAF V600E mCRC patients in BEACON-CRC (NCT02928224); BRAF V600E CRC COMPANION DIAGNOSTIC: FoundationOne CDx or cobas 4800 BRAF V600 test — BRAF V600E in patient colorectal cancer FFPE (somatic, approximately 8–12% of all CRC); BRAF V600E CRC HISTORY: historically BRAF V600E mCRC was treated with standard chemotherapy (BRAF inhibitor monotherapy failing due to EGFR feedback); vemurafenib + cetuximab (VinCe trial) showed some signal; BEACON-CRC established encorafenib + cetuximab as standard of care with OS HR 0.61; COMPANION DIAGNOSTIC PARADOX: BRAF V600E detected in patient colorectal tumor FFPE is a somatic variant — the oncology nurse or pharmacist preparing encorafenib capsules at Dana-Farber does not have BRAF V600E in their somatic cells unless they independently have a BRAF-mutant tumor; NIOSH HD Category 1 H340 H350 H361 hazard applies to encorafenib handlers regardless of their own BRAF genotype; EHS Insight at Dana-Farber: CAS 1269440-17-6 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; BRAF long-residence-time absent; BEACON-CRC CRC absent; BRAF three-NDA-holder class null absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne encorafenib 0.00016 µg/m³; impinger + LC-MS/MS; displayed (÷10): 0.000016 µg/m³; 38M colorectal GI oncology pharmacist BRAF encorafenib BEACON-CRC 12yr]).

Integrating Glyphward into Encorafenib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every encorafenib CAS 1269440-17-6 monitoring data ingestion point — before Cority at Pfizer Inc. New York NY, before VelocityEHS at Lonza AG Basel Switzerland, and before EHS Insight at Dana-Farber Cancer Institute Boston MA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent from all OEL databases (genotoxicity/reproductive toxicity independent of BRAF genotype) [10 pts]; THIRD BRAF + BRAF three-NDA-holder class null (vemurafenib Roche/Genentech NDA 202429 August 2011 + dabrafenib Novartis NDA 202806 May 2013 + encorafenib Array/Pfizer NDA 210496 June 27 2018 #545) + FIRST long-residence-time BRAF V600E (t½ >30h) + FIRST CRC BRAF NDA + same-day Array dual NDA (with binimetinib NDA 210498) [5 pts]; Pfizer New York NY + Lonza Basel Switzerland + Dana-Farber Boston MA [3 pts]; BRAF V600E extended dissociation kinetics absent from OEL derivation documents; BRAF V600E CRC somatic not worker; BEACON-CRC doublet/triplet combinatorial scope absent from OEL frameworks; NIOSH HD Category 1 H340 H350 H361 applies to all encorafenib workers independent of BRAF genotype [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_encorafenib(cas: str, reading_ugm3: float) -> dict:
    """Scan encorafenib with BRAF-three-NDA-holder-class-null + long-residence-time context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1269440-17-6"
                "reading_ugm3": reading_ugm3,
                "context": "third_braf_braf_three_nda_holder_class_null_first_long_residence_time_braf_first_crc_braf_approval_beacon_crc_same_day_array_dual_nda"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, braf_long_residence_flag, braf_three_nda_holder_class_null,
    #                    first_array_pfizer_braf_null, beacon_crc_flag,
    #                    braf_v600e_crc_companion_flag, same_day_dual_nda_flag,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_encorafenib("1269440-17-6", 0.00037))
    print(r)
    # {'hd_category': 1, 'braf_long_residence_flag': True,
    #  'braf_three_nda_holder_class_null': True, 'first_array_pfizer_braf_null': True,
    #  'beacon_crc_flag': True, 'braf_v600e_crc_companion_flag': True,
    #  'same_day_dual_nda_flag': True, 'h340_h350_h361_absent': True}